Podcasts about Bladder cancer

Send us Fan Mail

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

Send us Fan Mail

Are traditional bladder cancer care models falling behind as new therapies flood the field and reshape the landscape? In this episode of BackTable Urology, Dr. Bogdana Schmidt talks with Dr. Amy Luckenbaugh and DNP/APP Meredith Donahue about building a co-managed intravesical therapy clinic that rethinks care for patients with non–muscle invasive bladder cancer (NMIBC). With innovative agents increasing patient volume and complexity, the team discusses adapting care models to new realities. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Why Clinic Models Need to Change Now04:03 - Overcoming Financial and J-Code Hurdles11:04 - High Volume Workflow14:10 - Pharmacy Coordination And Timing19:02 - Proactive Lower Urinary Tract SYmptom Management22:25 - Handling Difficult Catheters32:08 - Defining Clinic Success --- More about this episode The conversation covers prioritizing clinical trials, managing operational challenges such as prior authorizations and billing hurdles, and the importance of pharmacy coordination and predictable clinic workflows. Donahue describes a high-efficiency installation day model managing up to 50 patients a week with specialized staff, real-time decisions, and tailored logistics for therapies like Adstiladrin. They also discuss symptom prevention, patient triage, and clinic success measures including therapy availability, patient satisfaction, and opportunities to preserve bladder function. --- Resources Gemcitabine IDRS Drug Delivery Trialhttps://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.635 BCG-IO Combination Trialhttps://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-approved-in-us-for-early-bladder-cancer.html --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Feeling overwhelmed after a bladder cancer diagnosis? Wondering where to turn for trusted information, emotional support, or practical guidance? In this episode of Bladder Cancer Matters, host Rick Bangs sits down with BCAN's Director of Education and Advocacy, Patricia Rios, for an inside look at the many free resources designed to help patients, caregivers and families navigate bladder cancer with more confidence and less fear. From one-on-one peer support and patient summits to clinical trial tools, webinars, caregiver resources, support groups, survivorship planning, and even BCAN's mobile app, Patricia shares how BCAN helps people feel informed, empowered, and—most importantly—not alone. Whether you're newly diagnosed, supporting a loved one, or looking for new ways to connect and advocate, this episode offers practical tools, hope, and a roadmap to the bladder cancer community.

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.CHAPTERS: 00:00 — Introduction: The Blood Test Number Better Than Cholesterol 00:35 — What Is Lymphopenia and Why It Matters 01:50 — Immunosenescence: Why Your T Cells Decline After Age 20 02:30 — The Mortality Data: Three Studies on Lymphopenia 03:20 — Copenhagen Study: 63% Higher All-Cause Mortality 03:50 — Coronary Angiography Study: Hazard Ratio 1.97 04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells 05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer 06:00 — Four Hallmarks of Aging Hit By One Molecule 06:30 — ANKTIVA Explained: The IL-15 Super-Agonist 07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe 08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case 09:00 — The Skeptical Case: Why We Don't Know Yet 10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally 11:30 — Final Take and ClosingKEY TAKEAWAYS:Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studiesIL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancerResistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay youngANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatmentIL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopeniaHonest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this spaceSTUDIES & SOURCES MENTIONED:Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adultsBawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patientsFDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancerWatch the full video on YouTube: https://youtu.be/220KHIdFCwg

Send us Fan MailBladder cancer treatment is entering a new era. From gene therapy and bladder preservation to AI-assisted diagnostics and the challenge of detecting “hidden” CIS, Dr. Ravi Chauhan, MD, FACS breaks down the technologies and clinical decisions reshaping urology in 2026.Dr. Ravi Chauhan, MD, FACS ( https://conradpearson.com/our-specialists/ravi-d-chauhan-m-d-facs/ ) is a board-certified urologist, fellowship-trained uro-oncology specialist, and one of the leading voices in advanced kidney and bladder cancer care in the Mid-South.Born and raised in Memphis, Tennessee, Dr. Chauhan graduated Cum Laude from Rhodes College with a degree in molecular biology before earning his M.D. and completing both his general surgery internship and urologic surgery residency at The University of Tennessee Health Science Center. He joined the Conrad Pearson Clinic in 2005 and has since become a recognized leader in the treatment of advanced bladder and kidney cancers, with numerous publications and presentations to his name.Dr. Chauhan's path into medicine was deeply personal. Inspired by watching his father practice medicine and witnessing the profound impact physicians can have on patients and families, he developed a philosophy centered on treating every patient with the same compassion, respect, and attention he would want for his own family.In addition to his expertise in surgical urology and uro-oncology, Dr. Chauhan has become increasingly focused on one of the biggest challenges in modern bladder cancer management: identifying and treating high-risk non–muscle invasive bladder cancer - or NMIBC, particularly  carcinoma in situ - or CIS , which can often be difficult to detect in routine clinical practice.Today, we'll discuss the evolving diagnostic landscape for CIS, why missed or under-recognized disease can significantly impact treatment decisions, and the growing importance of collaboration between urologists and pathologists. We'll also explore how community urologists are navigating these rapidly evolving standards of care, the future of precision bladder cancer management, and what it means for patients facing this disease.We'll also discuss bladder-sparing approaches, including Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy for adults with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC with CIS, with or without papillary ( https://www.adstiladrin.com/ ).ADSTILADRIN should not be used in patients with hypersensitivity to interferon alfa or its components, and individuals who are immunosuppressed or immune-deficient should not handle or receive the therapy. Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.The most common adverse reactions include urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in urine. Patients should consult their healthcare provider regarding all medications and report any side effects. Please see full Prescribing Information  ( https://d2hu1op93domjx.cloudfront.net/wp-content/uploads/sites/12/2026/03/24101239/ADSTILADRIN-USPI-Mar.2026-CLEAN.pdf ) for additional details.#BladderCancer #Urology #CancerResearch #BladderCancerAwareness #NMIBC #CarcinomaInSitu #CIS #UroOncology #GeneTherapy #CancerTreatment #PrecisionMedicine #BCG #BladderPreservation #MedicalInnovation #Oncology #CancerCare #Immunotherapy #HealthcareInnovation #UrologistSupport the show

To mark Bladder Cancer Awareness Month in May, The Bladder Cancer Advocacy Network hosts the Walk to End Bladder Cancer on May 31st in Manhattan’s Hudson River Park, Pier 25. More than 725,000 people in the United States are living with bladder cancer, yet its warning signs are often missed until everything changes—and outcomes are worse for women at every stage. Bladder cancer survivors Shannon van Heerden and Sandy Weicher, tell their stories and urge others to trust their instincts when something feels wrong. See omnystudio.com/listener for privacy information.

Host: Darryl S. Chutka, M.D  Guest: Mark D. Tyson, III, M.D., M.P.H.  Bladder cancer is one of the most common malignancies worldwide, and primary care clinicians are often the first to evaluate patients with bladder cancer. The symptoms are usually subtle and may include either gross or microscopic hematuria. The decision in whether to investigate these presenting symptoms can often impact early diagnosis and the patient's outcome. When should we investigate hematuria? What should an evaluation of hematuria consist of? What is the treatment for bladder cancer? How should patients with recurrent bladder cancer be managed? What role does the primary care clinician play in the long-term management of patients? I'll be asking these questions and more of my guest, Dr. Mark Tyson, a urologist at the Mayo Clinic as we discuss “Bladder Cancer”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Dr. Trinity Bivalacqua on the first results from CORE-008 Cohort CX- phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in patients with high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. They talk in detail of the rational and results of this cohort, and the role of cretostimogene in treatments of BCG-exposed or BCG-unresponsive bladder cancer. For more details on this study, you can read the abstract on the UROONCO BCa Educational Platform.This interview was recorded at AUA2026. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies

https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Cystitis (1:45),Pyelonephritis (5:11),Asymptomatic Bacteriuria (6:42),Benign Prostatic Hyperplasia (8:10),Acute Bacterial Prostatitis (9:43),Acute Urinary Retention (11:12),Stress Urinary Incontinence (12:29),Urge Incontinence (13:43),Overflow Incontinence (15:04),Nephrolithiasis (16:31),Testicular Torsion (19:15),Epididymitis (21:12),Hydrocele (23:23),Varicocele (24:48),Spermatocele (26:40),Testicular Cancer (27:28),Bladder Cancer (29:29),Renal Cell Carcinoma (30:40),Prostate Cancer (32:56),Practice Questions (35:40).

Episode 148: Bladder Cancer Awareness: Why "Invincible" Athletes Aren't Immune by Steven Frey

    Michelle Reed is still with us after being diagnosed with NMI bladder cancer in 2018; but she will stop short of saying she has survived the disease.  Since surgery to remove a 7mm mass, she has had ten recurrences.  Post-treatment included a chemotherapy regimen of gemcitabine, which she says she will be taking for the rest of her life.  Managing her cancer consists of making she comes in for her scheduled scans and listening to her body.  Michelle does much to help others as they battle cancer through her book and her website.   In 2018, Michelle Reed had a lot on her plate.  Her son had just been in an auto accident and while she was caring for him and working at a full time job, she noticed blood in her urine.  With all she had going on, she was slow to seek medical attention, but when the condition wouldn't go away, she went to an urgent care.  She made five such visits, each time being told she probably just had a urinary tract infection or mini kidney stones.  Michelle had friends who had suffered kidney stones, knew they were quite painful, and that tipped her off, that the diagnoses she had received at the urgent care were inaccurate.   She eventually saw a urologist who conducted a FISH test, which stands Fluorescence In Situ Hybridization urinalysis, which combined with a CT scan, revealed a 7mm mass on her bladder.  Her doctor said it was urgent that Michelle undergo surgery to remove the mass.  He added that a best-case scenario was complete removal of the mass after which she could go home, while a worst-case scenario would her being hooked up to a bag for the rest of her life.  Thankfully, the entire mass was removed.    However, Michelle Reed will never say she has 'survived' bladder cancer.  After the surgery, she was put on a chemotherapy regimen of gemcitabine.  She says she will always be on that regimen.  Michelle also says since her diagnosis, she has had no less than ten recurrences of bladder cancer, but none have required surgery.  She just knows there is the possibility that another surgical procedure could be in her future.   Michelle says the quality of her urinary function varies from day to day, and that also will be with her for the rest of her life, as well as fatigue that is a byproduct of her treatment.   By way of advice to others who find themselves 'managing' their cancer, she says to be sure to be present for all your scheduled appointments and listen to your body.   Michelle Reed makes a steadfast effort to help others battling cancer with a book anda website.   Additional Resources:   Michelle's Book: Cancer Care Book   Michelle's Website: https://www.cancersupportstudio.com  

John Walker Pattison is still with us despite two protracted battles with cancer.  He was diagnosed with Stage IV Hodgkin lymphoma in 1975 and relapsed three times.  Then in 2018, he was diagnosed with bladder cancer, a diagnosis after which he relapsed once.  After his lymphoma diagnosis, treatment included an aggressive chemotherapy regimen, which included nitrogen mustard, vincristine, procarbazine and prednisolone.  John said effects from the chemo hampered his fight with bladder cancer and still affect him today, although his urinary function is just fine.    John was in his late teens when he began to experience fatigue, night sweats, recurring cough and weight loss, among other symptoms.  He was doing heavy lifting in the shipbuilding business, had difficulty at work and one day on the job he collapsed.  Realizing he needed medical attention, he underwent scans and biopsies, and they led to a diagnosis of Stage IV Hodgkin lymphoma.  He was told his chances of recovery were slim.   In May 1975, his care team prescribed a chemotherapy cocktail of nitrogen mustard, prednisolone, procarbazine and vincristine, which only added to a high degree of fear he had for his future.    Things went from bad to worse when he was informed that the chemo regimen didn't work and he relapsed.  In April 1976, he was put on a different regimen with cyclophosphamide taking the place of nitrogen mustard.  That, too, was ineffective, resulting in another relapse.  In December of that year, his care team tried radiotherapy, again with no success.    In April 1977, John went on a regimen of palliative chemotherapy, with single agent vinblastine.  On a subsequent visit, his oncologist raised his arms in triumph and shocked John by telling him he was cancer free.   John Walker Pattison thought cancer was in his rear-view mirror, but in 2018, while traveling by air, he discovered blood in his urine.  He was a health care professional and immediately knew something was wrong.  Again seeking medical attention, he was diagnosed with Grade II Transitional Cell Bladder Carcinoma.  He underwent surgery, followed by bladder installation of mitomycin chemotherapy.  That was followed by transurethral laser ablation in 2020.  Not long after that procedure, again, John was told he was cancer free.   John Walker Pattison enjoys normal urinary function, but says he will be dealing with the side effects of the chemotherapy and radiotherapy he underwent in the seventies.   That said, John wants to help others diagnosed with cancer.  He has written a book, "Shadow of a Survivor," which he hopes will be a source of hope and inspiration.   Additional Resources:   John's Book, "Shadow of a Survivor," available on Amazon John's Website, https://www.johnpattison.co.uk  

From practical risk stratification to the real-world challenges of delivering BCG, Dr. Aly-Khan Lalani and Dr. Christopher Wallis lead a conversation with Dr. Kulkarni about non-muscle invasive bladder cancer and its rapidly evolving treatment landscape. Dr. Kulkarni is a urologic surgeon at the Princess Margaret Cancer Centre, University Health Network, and a surgeon-scientist and Assistant Professor at the University of Toronto. As a thought leader in bladder cancer, he shares key clinical decision points, patient-centred considerations, and practical strategies that clinicians can apply today.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making.The conversation also tackles the unique challenges of Upper Tract Urothelial Carcinoma. From evidence gaps in upper tract care to the complexities of trial design, this episode offers a forward-looking map of the evolving urothelial cancer landscape.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of metastatic urothelial carcinoma management, contrasting historical standards with the rapidly evolving frontline paradigm. As the field transitions into a new era of care, Drs Armstrong and Tawagi emphasized the importance of understanding trial data and toxicity management for both board preparation and clinical practice.The discussion began with details about the historical treatment paradigm, which relied on platinum-based chemotherapy followed by maintenance avelumab for patients who did not progress. However, the experts noted that the current SOC has shifted dramatically following findings from the landmark EV-302 trial, which evaluated the combination of enfortumab vedotin and pembrolizumab.They also explained that the toxicities associated with enfortumab vedotin plus pembrolizumab are highly testable and clinically relevant. Key adverse effects include skin toxicity and peripheral neuropathy, they said. Additionally, the hosts highlighted hyperglycemia and the risk of diabetic ketoacidosis, and emphasized that ocular toxicities, specifically dry eyes, also necessitate referrals to ophthalmology.In the second-line setting following enfortumab vedotin plus pembrolizumab, Drs Armstrong and Tawagi noted that the paradigm unclear, though treatment options include platinum-based chemotherapy or targeted agents. They recommended testing for FGFR mutations to determine patient eligibility for erdafitinib, as well as testing for HER2 expression to determine eligibility for trastuzumab deruxtecan.They also reported that for localized high-grade upper tract urothelial carcinoma, treatment options include neoadjuvant split-dose gemcitabine/cisplatin or upfront surgery followed by adjuvant chemotherapy. In the metastatic setting, they noted that rare disease variants like small cell carcinoma are treated with platinum doublets and immunotherapy, whereas adenocarcinoma management may require FOLFOX.

Today's episode is focusing on what you need to know regarding metastatic bladder cancer, with 2026 updates. This will include the need to know treatment options and toxicities for metastatic urothelial carcinoma, and also discuss the management of upper tract + variant non-urothelial histology.

May 1, 2026In this episode, Scott, Mark, and Dr. Ray Painter break down key differences between ureteral stent removal and replacement codes—50385, 50387, and 50688—highlighting how anatomy, access (internal vs. external), and the requirement for radiologic supervision drive proper code selection. They also tackle a growing issue with ICD-10 coding for bladder cancer, where the correct use of “history of” codes during BCG maintenance therapy is leading to unexpected payer denials. The discussion explores when to follow strict coding guidelines versus when payer-specific rules may require strategic adjustments. The takeaway: understanding both the technical details of coding and the realities of payer behavior is essential to avoiding denials and protecting revenue. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Anna Rozzi tells us about the bladder cancer research she is doing at OHSU. We need more fire fighters to take the survey. Click here https://ohsu.ca1.qualtrics.com/jfe/form/SV_aW5VrH58N60Of1I or on the QR code to help out.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of localized bladder cancer, covering everything from initial histology to the rapidly evolving treatment paradigms for muscle-invasive disease. Drs Armstrong and Tawagi emphasized that although urothelial carcinoma remains the most common bladder cancer histology, recognizing variants like squamous, adenocarcinoma, and small cell is vital, as they often require surgery-first approaches or specialized chemotherapy. A critical diagnostic pearl highlighted for oncology boards was the necessity of muscularis propria in the transurethral resection of the bladder tumor (TURBT) specimen. If muscle is absent, a repeat TURBT is mandatory to ensure the cancer is not under-staged. For non–muscle-invasive bladder cancer, the treatment goal is preventing recurrence and progression. Patients with high-risk disease should receive BCG induction and maintenance. For those who are BCG unresponsive, Drs Armstrong and Tawagi discussed several novel intravesical therapy options that may be preferred over systemic pembrolizumab to avoid toxicity.The management of muscle-invasive bladder cancer (MIBC) is primarily dictated by cisplatin eligibility, which is determined by performance status, renal function, and the absence of neuropathy or hearing loss. In cisplatin-eligible patients, the phase 3 NIAGARA trial (NCT03732677) results led to a new standard of care (SOC), which is the addition of durvalumab (Imfinzi) to a gemcitabine/cisplatin backbone. Furthermore, the phase 3 KEYNOTE-B15 trial (NCT04700124) data demonstrated that neoadjuvant enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) significantly improved overall survival compared with standard chemotherapy, though this combination is not yet the board-tested standard. For cisplatin-ineligible patients, the phase 3 EV-303 trial (NCT03924895) established neoadjuvant enfortumab vedotin plus pembrolizumab as a new SOC, replacing the previous approach of upfront cystectomy followed by adjuvant nivolumab (Opdivo).Finally, Drs Armstrong and Tawagi discussed trimodal therapy as a bladder-sparing treatment approach. Ideal candidates for this approach must have small tumors, a complete TURBT, no hydronephrosis, and must commit to lifelong cystoscopic surveillance.

Today's episode is focusing on what you need to know regarding localized bladder cancer, with 2026 updates. This will include the need to know pathology, presentation, diagnostic work-up, staging, and treatment options. 

This week's episode will be focusing on how we met, the future of the podcast, and why we picked heme/onc. This is a very different style of episode and a special once because this month is our 4 year anniversary of Two Onc Docs! And we will back to our regular programming next week with overdue updates on Bladder Cancer.

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A woman in her early 60s with muscle-invasive bladder cancer experiences disease progression with lung metastasis after surgery and receives enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his mid 70s with metastatic urothelial bladder cancer (UBC) starts first-line EV/pembrolizumab with a partial response, and testing reveals HER2 IHC 3+ (10:58) Case: A man in his late 60s with progression of metastatic UBC after multiple lines of therapy for whom testing reveals HER2 IHC 3+ receives trastuzumab deruxtecan (19:18) CME information and select publications

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.CME information and select publications here.

 Today on Beating Cancer Daily, Stage IV survivor Saranne Rothberg brings humor, personal stories, and science to an episode focused on bladder health, featuring insights on bladder function, symptoms of bladder issues, and practical strategies for maintaining a healthy urinary system. Saranne shares memorable experiences with bladder emergencies and kidney stones, while her recurring guest, Jacqui Bryan, brings expertise and actionable advice to support listeners battling bladder irritations, infections, or even bladder cancer. From the importance of hydration to recognizing symptoms such as urine discoloration, the discussion emphasizes proactive care and attention to the body's signals. Jacqui Bryan is a functional medicine expert, certified health coach, certified nutrition specialist, whole health educator, and registered nurse. Her multidisciplinary credentials equip her to deliver practical nutrition and lifestyle strategies for bladder health, and her experience spans from pelvic floor strength to dietary recommendations for managing inflammation and bladder discomfort. "I just want to let you know, the bladder always wins." ~Saranne Today on Beating Cancer Daily:·     Bladder irritation and infections are common, but lifestyle strategies can help reduce risk and discomfort.·     Hydration is the foundation of bladder health; moderate, consistent water intake is key.·     Symptoms like urgency, frequency, night waking, leaking, discomfort, and changes in urine color warrant attention.·     Foods and drinks that can irritate the bladder include caffeine, alcohol, spicy foods, acidic fruits, artificial sweeteners, and carbonated beverages.·     Incomplete bladder emptying, such as from squatting instead of sitting in public bathrooms, can increase stone risk.·     Kegel exercises support bladder health in both men and women, especially after childbirth or with aging.·     Dietary fiber helps prevent constipation, which can worsen bladder urgency and leakage.·     Healthy fats and lean proteins support cell health and help reduce bladder inflammation; be mindful of late-night fluid and sodium intake. Guest Contact Information:Jacqui Bryan: JacquiBryan.com  2025 - 2026 People's Choice Podcast Awards Best Health Series Finalist Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024, 2025 & 2026, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025.Beating Cancer Daily is listened to in 144 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_SuggestionsTo sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pooja Ghatalia, MD Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearance correlates with improved metastasis-free survival and informs risk stratification, is Dr. Pooja Ghatalia. She also examines the strengths and limitations of ctDNA, including its prognostic value for systemic recurrence and its inability to reliably detect localized disease. Dr. Ghatalia is an Associate Professor in the Department of Hematology and Oncology at Fox Chase Cancer Center at Temple University Hospital in Philadelphia, and she presented this research at the 2026 ASCO Genitourinary Cancers Symposium.

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving treatment algorithms for bladder cancer following the latest data presented at GU ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore: The role of immunotherapy in non-muscle invasive bladder cancer, highlighting the recent positive trials: CREST with Sasanlimab and POTOMAC with Durvalumab. Insights on the current standard of care and the implications of combining BCG with immunotherapy. The shift in treatment strategies for muscle-invasive bladder cancer, including the new standard of care with the EV-Pembro combination and its impact on pathologic complete response rates. The challenges and considerations in managing side effects associated with new therapies, as well as the importance of patient selection and coordination between urologists and medical oncologists. The emerging role of ctDNA in guiding treatment decisions and the ongoing discussions around the sequencing of therapies in refractory settings. Hope you enjoy this informative discussion that aims to keep you up to date in the world of cancer treatment, here focusing on bladder cancer. Subscribe to our channel for more episodes and discussions on the latest in oncology! #BladderCancer, #NMIBC, #MIBC, #Immunotherapy, #GU26, #OncologyBrothers

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33) Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07) CME information and select publications

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.

Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Introduction (0:00) Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27) Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30) Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56) Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47) CME information and select publications

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic's Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.CME information and select publications here.

In this powerful episode of Bladder Cancer Matters, a podcast by the Bladder Cancer Advocacy Network, host and survivor Rick Bangs sits down with Vanderbilt nurse Bree Duncan to explore a groundbreaking new role dedicated solely to supporting women with bladder cancer. Created through the vision and generosity of a grateful patient, this female bladder cancer care coordinator position is transforming how women—especially those facing radical cystectomy - experience care, offering direct access, emotional support, faster answers, and a steady, compassionate presence during one of the most overwhelming times of their lives.  Bree shares how this innovative model is reducing ER visits, easing fear, improving recovery, and even inspiring cancer centers beyond the U.S. If you care about health equity, patient-centered care, or simply want to hear what's possible when compassion meets action, this episode will leave you hopeful—and maybe a little inspired to help spark change where you are.

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable residual disease detection Presenters: Sam S. Chang, MD, MBA Patricia and Rodes Hart Chair of Urologic Surgery Chief Surgical Officer Vanderbilt Ingram Cancer Center Nashville, Tennessee Matthew D. Galsky, MD Lillian and Howard Stratton Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Genitourinary Medical Oncology Co-Leader, Cancer Clinical Investigation Program Associate Director for Translational Research Tisch Cancer Institute New York, New York Link to full program: https://bit.ly/479RgQn Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fixation on Histology: A New Approach to Bladder Cancer Detection Written based on the research article published in the Journal of Histotechnology To Read the Full Blog, Click Here.  

Robotic pets make life easier for patients with dementia; Risks, benefits of “natural” ED formulas; Sorting out those pricey new injectable osteoporosis drugs; Daily multivitamin delays biological aging; Study challenges notion that aging means inevitable decline; Breastfeeding confers weight loss benefits—to moms; Can you avoid a colonoscopy with a new colon cancer blood test? Color blindness may hide warning signs of cancer.

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS. EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65. LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia. CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported.  Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

We had the opportunity to dive into the evolving landscape of bladder cancer treatment in this insightful podcast episode at GU ASCO 2026. Featuring expert guests Dr. Chad Reichard, Dr. Shilpa Gupta, Dr. Matt Galsky, and Dr. Sia Daneshmand, the discussion covered the latest FDA-approved options for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), and exciting data that we are seeing presented at GU ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ In this episode, you'll learn about: The current treatment options for MIBC, including neoadjuvant Gem/Cis with perioperative durvalumab vs. EV/pembrolizumab combination Key findings from pivotal studies like KEYNOTE-905, NIAGARA, and KEYNOTE-B15 The implications of these studies on clinical practice and patient management The importance of a multidisciplinary approach in treating bladder cancer Emerging data on BCG plus immunotherapy combinations for NMIBC and their potential impact on treatment protocols Tune in for a comprehensive discussion that highlights the importance of collaboration between medical oncologists and urologists in optimizing patient care. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #BladderCancer, #MIBC, #NMIBC, #Immunotherapy, #EVpembro

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

AUA2025: Key Takeaways: Bladder Cancer Presenters: Patrick Hensley, MD & Janet Kukreja, MD

Featuring an interview with Dr Terence Friedlander, including the following topics: Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00) Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17) TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19) CME information and select publications

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00) Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39) Case: A fit man in his early 70s presents with metastatic disease (15:22) CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics: Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00) KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25) The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07) Circulating tumor DNA-guided therapies for MIBC (18:41) CME information and select publications